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doi:10.1016/j.ejvs.2008.08.021Abstract Objective: To compare the proportion of foam sclerosant that enters deep veins
between multiple injections of <0.5 ml foam per injection and a few injections of >0.5 ml
foam per injection.
Design & methods: One hundred and seven patients with superficial venous incompetence
were randomised to receive either multiple injections of <0.5 ml 1% polidocanol (POL) -foam
(multiple injections) or a few injections of >0.5 ml 1% POL-foam per injection (few injections)
for the treatment of varicose tributaries. All patients then received ultrasound-guided foam
sclerotherapy for refluxing great saphenous vein (GSV) using 3% POL-foam. Only a single session
was allowed per patient in order to standardise treatment. Qualitative ultrasonographic
inspection of the foam was carried out during a 5-min period before compression was applied.
Post-sclerotherapy surveillance was done at day 3, 2 weeks, 1 month, 3 months, and 6 months.
Results: Fifty-six limbs in 53 patients were treated with multiple injections and the remaining
56 limbs in 54 patients were treated with a few injections. There were no significant differ-
ences in age or male:female ratio between the groups. The mean volume of 1% POL-foam
was 2.2 S.D. 0.6 ml (range: 0.7e4.0 ml) in the multiple injections group and 2.5 S.D. 0.6 ml
(range: 1.0e4.0 ml) in the few injections group (pZ 0.003). The mean volume of 3% POL
was 1.5 ml (range: 0.7e3.0 ml) and 1.4 ml (range: 0.7e3.0 ml), respectively (pZ 0.137).
Ultrasonographic inspection immediately after sclerotherapy demonstrated that foam was
distributed significantly more commonly in the deep veins of patients treated with a few injec-
tions (pZ 0.0003). Two (4%) of the patients treated with a few injections developed migraine
during the procedure, but recovered quickly with no further complications. There was no
significant difference in the success rate between the groups at 6 months (pZ 0.257).3353 8111; fax: þ81 3 3225 0940.
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344 T. Yamaki et al.Conclusions: These findings suggest that multiple small-dose injections can reduce the amount
of foam sclerosant and the risk of foam sclerosant entering the deep veins in patients with
superficial venous insufficiency.
ª 2008 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Introduction
Compression sclerotherapy is associated with a significantly
higher recurrence rate than surgical intervention1,2 and is
used as an adjunct for treating varicose tributary veins.3e5
Ultrasound-guided liquid sclerotherapy has been recognised
as an alternative to surgical interruption for control of
saphenous junctional incompetence.6e12 Ultrasound-guided
foam sclerotherapy is considered promising in the
management of saphenous truncal incompetence.13e27
Compared to liquid sclerosants, the dose of foam sclerosant
can be reduced in both volume and concentration.27 This
has been confirmed by histological studies of human
endothelial cells.28
However, one possible hazardous complication that may
be associated with foam sclerotherapy is air embolism. A
patent foramen ovale (PFO), possibly responsible for
paradoxical embolism, occurs in up to 27% of the pop-
ulation.29 This complication may be minimized if a large
amount of foam sclerosant does not enter the deep venous
system.22,23,29,30 Furthermore, it is likely to spill over into
deep veins if more than 0.5e1.5 ml of solution is injected at
a single side.31 Therefore, the purpose of this study was to
compare the proportion of foam sclerosant entering the
deep veins between multiple injections of polidocanol
(POL) foam using <0.5 ml per injection and a few injections
of POL-foam using >0.5 ml per injection for varicose trib-
utary veins in order to establish a safer injection
procedure.
Materials and Methods
Patients
Between January 2007 and October 2007, 112 limbs in 107
patients who had isolated great saphenous vein (GSV) reflux
associated with SFJ incompetence were selected for
ultrasound-guided foam sclerotherapy (UGFS) at the
Department of Plastic and Reconstructive Surgery, Tokyo
Women’s Medical University. Patients were prospectively
randomised to receive either multiple injections of POL-
foam using <0.5 ml per injection (multiple injections: 3
injections or more) or a few injections of foam using
>0.5 ml per injection (few injections: less than 3 injec-
tions). The patients comprised 29 male and 78 female
patients with a mean age of 65 (range: 24e87) years. The
clinical manifestations of these patients were categorized
according to the CEAP (clinical, aetiologic, anatomic, and
pathophysiologic) classification of reporting standards for
venous disease.32,33 All of the patients’ lesions were clas-
sifiable as C2,3,4a,4b,5,6,S, Ep, As, Pr2,3. Patients with
myocardial ischaemia, arterial insufficiency with an ankle
brachial index of less than 0.9, pregnancy in the firsttrimester and after the 36th week of gestation, local
infection in the area of sclerotherapy, active thrombo-
phlebitis and acute deep vein thrombosis were excluded.
Patients were followed up for 6 months following treat-
ment. This study was approved by the institutional review
board, and informed consent was obtained from all
participants.
Pre-treatment evaluation
A diagnostic examination was performed using colour
duplex ultrasonography (LOGIQ 7 PRO; GE Yokogawa
Medical Systems, Tokyo, Japan) with a 5- to 10-MHz trans-
ducer to detect venous reflux at the SFJ and in the GSV.
Venous reflux was assessed with the patient standing. For
evaluation of the SFJ, a pneumatic thigh cuff (Hokanson,
Bellevue, WA, USA) was attached to the thigh, inflated to
80 mmHg and then rapidly deflated. For evaluation of the
GSV, a cuff was applied to the calf, inflated to 100 mmHg
and then rapidly deflated. The diameter of the GSV was
measured in cross-sectional view 3e4 cm distal to the SFJ
with the patient standing. Venous reflux was considered to
be present if the reflux time exceeded 0.5 s.
Ultrasound-guided foam sclerotherapy (UGFS)
The sclerosing foam was produced by Tessari’s method
using 1% and 3% POL (Aethoxysklerol, Kaigen, Osaka,
Japan).18 Foam was obtained from 0.5 ml of liquid polido-
canol mixed with air at a ratio of 1:4 using a three-way
stopcock to mix the sclerosant.
Because one of the purposes of this study was to
compare the success rate between the two groups, all
patients received only one treatment session during the
follow-up period of 6 months. After detailed anatomical
mapping with duplex ultrasound, patients were placed
supine with their affected legs elevated 30 degrees. Each
visible varicose tributary vein was injected first, with
multiple injections or a few injections, using 27-gauge
needles. In patients who received multiple injections, the
number of injections depended on the locations of the
varicose veins. In contrast, only 1e3 injections were used
to occlude varicose tributaries in patients who received few
injections. Then 3% POL-foam was injected under ultra-
sound guidance using 21-gauge needles, starting 3e4 cm
distal to the SFJ,11 and a second injection was made
5e10 cm distal to the initial point. Ultrasonographic
inspection of the foam was then performed for 5 min before
compression was applied. Ultrasonographic monitoring
began with ankle (AP), leg (LP) and knee perforators (KP),
and was moved to the posterior (PTV) and anterior tibial
(ATV), peroneal (PV), soleal (SV) and gastrocnemius veins
(GV). Afterwards, the popliteal (POPV), femoral (FV),
common femoral veins (CFV), and thigh perforators (TP)
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scored as present or absent in each vein.
Post-sclerotherapy follow-up
To evaluate the early complications and efficacy of UGFS,
post-sclerotherapy surveillance was done at day 3, 2 weeks,
1 month, and 3 and 6 months using duplex ultrasound.
Findings obtained by duplex scanning 6 months after scle-
rotherapy were divided into four groups:
(1) Complete occlusion group: the GSV was occluded and
was totally shrunk
(2) Partial recanalisation with no reflux: the GSV was
partially recanalised with no evidence of reflux
(3) Partial recanalisation with reflux: the GSV was partially
recanalised with reflux
(4) Complete recanalisation with reflux: the GSV was
totally recanalised with refluxTable 2 Ultrasonographic inspection of POL-foam
Multiple injections
(nZ 56 limbs)
A few injections
(nZ 56 limbs)
p-value
Deep veins 17 (30.4%) 36 (64.3%) 0.0003
CFV 12 (21.4%) 31 (55.4%) <0.0001
FV 13 (23.2%) 35 (62.5%) <0.0001
POPV 11 (19.6%) 33 (58.9%) <0.0001Statistical analysis
All data were analysed using StatView for Windows (Version
5.0, SAS Institute Inc., Cary, NC). Wilcoxon’s nonparametric
rank sum test was used to estimate differences between
numerical data, and chi-squared contingency table analysis
was used to evaluate differences between proportions.
Continuous data were expressed as mean and standard
deviation (S.D.). Statistical significance was defined as
p < 0.05.
Results
Patients
Table 1 summarises the baseline characteristics of the two
study groups. Fifty-six limbs in 53 patients were treated
with multiple injections and 56 limbs in 54 patients were
treated with a few injections. There were no significant
differences in age or male:female ratio. The mean diam-
eter was 6.7 S.D. 1.4 mm for each group, and no significant
difference was found in the mean diameter between theTable 1 Baseline characteristics of the study patients
Multiple injec
tions (nZ 53
patients)
A few injec
tions (nZ 54
patients)
p-value
Mean age (years) 65.0  12.6 64.4  10.0 0.594
Gender (female) 41 (77.4%) 36 (66.7%) 0.218
Diameter of
GSV (mm)
6.7  1.4 6.7  1.4 0.736
CEAP clinical
class
nZ 56 limbs nZ 56 limbs
C2 39 (69.6%) 41 (73.2%) 0.676
C4a 9 (16.1%) 7 (12.5%) 0.589
C4b 6 (11.3%) 7 (12.5%) 0.768
C5, C6 2 (3.6%) 1 (1.8%) 0.558groups. Similarly, there was no significant inter-group
difference in each CEAP class. Successful needle placement
and ultrasound-monitored foam injection was accom-
plished in all cases without complication.
Amount of sclerosing foam
There was no significant inter-group difference in the total
number of treated tributary varicose veins (2.5 S.D. 0.9, 2.4
S.D. 0.9, respectively; not significant). The mean number of
vein punctures was 5.3 for the multiple injections group
and 2.8 for the few injections group. Similarly, the mean
volume used for varicose tributary veins was 0.42 ml per
puncture for the multiple injections group and 0.87 ml per
puncture for the few injections group. The POL-foam
produced immediate spasm along the injected veins. The
mean volume of 1% POL-foam was 2.2 S.D. 0.6 ml (range:
0.7e4.0 ml) for the multiple injections group and 2.5 S.D.
0.6 ml (range: 1.0e4.0 ml) for the few injections group, and
there was a significant difference in the amount of scle-
rosant foam between the two groups (pZ 0.003). The
mean volume of 3% POL was 1.5 ml S.D. 0.5 (range: 0.7e
3.0 ml) for the multiple injections group and 1.4 ml S.D. 0.5
(range: 0.7e3.0 ml) for the few injections group, and there
was no significant difference in the amount of 3% POL-foam
between the two groups.
Ultrasonographic inspection
Table 2 shows the ultrasonographic inspection of the foam
performed during the 5 min after completion of foam
sclerotherapy and the proportion of veins showing the
presence of foam. Because spasm of the GSV and varicoseATV 2 (3.6%) 3 (5.4%) 0.647
PTV 4 (7.1%) 18 (32.1%) 0.0005
PV 0 (0%) 14 (25.0%) <0.0001
GV 6 (10.7%) 16 (28.6%) 0.017
SV 5 (8.9%) 19 (33.9%) 0.001
Perforating
veins
18 (32.1%) 40 (71.4%) <0.0001
TP 3 (5.4%) 12 (21.4%) 0.013
KP 14 (25.0%) 20 (35.7%) 0.218
LP 4 (7.1%) 12 (21.4%) 0.031
AP 1 (1.8%) 2 (3.6%) 0.558
Proportion of veins showing evidence of foam during 5 min of
surveillance following treatment.
POL, polidocanol; CFV, common femoral vein; FV, femoral vein;
POPV, popliteal vein; ATV, anterior tibial vein; PTV, posterior
tibial vein; PV, peroneal vein; GV, gastrocnemius vein; SV, sol-
eal vein; TP, thigh perforators; KP, knee perforators; LP, leg
perforators; AP, ankle perforators.
Table 4 Outcome of UGFS
Multiple injections
(nZ 56 limbs)
A few injections
(nZ 56 limbs)
p-value
Occlusion 29 (51.8%) 33 (58.9%)
Partial
recanalisation
with no reflux
12 (21.4%) 13 (23.2%)
Subtotal 41 (73.2%) 46 (82.1%) 0.257
Partial
recanalisation
with no reflux
6 (10.7%) 4 (7.1%)
Complete
recanalisation
with reflux
9 (16.1%) 6 (10.7%)
Subtotal 15 (26.8%) 10 (17.8%)
Total 56 (100%) 56 (100%)
Proportion of saphenous veins showing outcomes as classified in
the text 6 months following a single treatment session.
UGFS, ultrasound-guided foam sclerotherapy.
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patients, no additional injection was required. Foam was
detected in the deep venous system in 17 (30.4%) of the
patients who received multiple injections and in 36 (64.3%)
of the patients who received a few injections (pZ 0.0003).
Detailed anatomical examination using duplex ultrasound
demonstrated that foam was significantly more common in
patients who received a few injections in each venous
segment, with the exception of the ATV. Similarly, in
perforating veins, a significantly higher proportion of the
foam was found in patients who received few injections
(pZ 0.0001), and foam was significantly more common in
the thigh and leg perforators (pZ 0.013 and 0.031,
respectively).
Complications of UGFS
Table 3 shows the early complications related to ultra-
sound-guided sclerotherapy. Pain was detected in one (2%)
patient in both groups. Superficial thrombophlebitis was
also found in 2 patients in both groups. Two (4%) of the
patients who received a few injections developed migraine
during the procedure, but recovered quickly with no further
complications. No other serious complications, such as
allergic reactions, deep vein thrombosis, pulmonary
embolism, or cerebral infarction were found during the
follow-up period.
Follow-up
Table 4 shows the findings obtained by duplex ultrasound
6 months after the treatment. Follow-up ultrasound
demonstrated complete occlusion in 52% of patients in the
multiple injections group and in 59% of those in the few
injections group. Similarly, 21% of the patients who
received multiple injections and 23% of those who received
few injections showed partial recanalisation with no reflux.
Patients who received few injections had a higher success
rate, but this was not statistically significant. In contrast,
27% of the patients who received multiple injections
showed reflux in the GSV 6 months after treatment. Simi-
larly, in the few injections group, 18% of the patients
demonstrated reflux in the treated GSV.
Discussion
Because of its efficacy and safety, UGFS has gained great
popularity as a minimally invasive treatment for varicose
veins, and large case series have been reported.18,20,24,26,27Table 3 Complications of UGFS
Multiple injections
(nZ 53 patients)
A few injections
(nZ 54 patients)
Pain 1 (1.9%) 1 (1.9%)
Paraesthesia 0 (0%) 1 (1.9%)
Superficial
thrombophlebitis
2 (3.8%) 2 (3.7%)
Migraine 0 (0%) 2 (3.7%)
UGFS, ultrasound-guided foam sclerotherapy.Recent reports have focused attention on the safety of
foam for this purpose. Compared to liquid sclerosant, foam
sclerosant shows a greater tendency to provoke inflamma-
tion, and is associated with mild adverse effects including
pain, inflammatory signs, and skin pigmentation.34 Neuro-
logical complications including transient visual disturbance,
transient confusion, and even cerebral infarction have been
described.35e37 The gas mixture used to create the foam
determines bubble characteristics. Bubble life is shorter if
the oxygen concentration within the bubble is increased
and the nitrogen concentration is decreased.38 Morrison
et al. compared the incidence of side effects between
carbon dioxide foam and air-based foam, finding that
carbon dioxide foams reduce side effects.39
The On-Line International Event on Sclerosing Foam and
Patent Foramen Ovale (PFO) recommended a number of
procedures to prevent possible neurological complications.
These included requesting patients not to dress or put on
shoes and stockings by themselves, avoiding the Valsalva
manoeuvre, and avoiding constipation before the proce-
dure. However, the Committee did not reach a final
conclusion as to whether there was a clear relationship
between clinical events and the use of foam. While chronic
cerebral damage resulting from PFO has been suggested,
there has been no clear evidence of any acute cerebral
effects resulting from injection of foam.30
Our study had some potential limitations. The method of
assessing the deep veins for the presence of foam following
sclerotherapy is subjective and not quantitative. We
believe that it reflects the extent of foam in the deep veins
but acknowledge that the study was not done in a blinded
fashion. The total volume of foam injected is substantially
less than has been recommended in the recent 2nd Euro-
pean Consensus Meeting on Foam Sclerotherapy.23 This may
well have prejudiced the long-term outcome in these
patients. The 6-month follow-up period is sufficient to
judge the ultrasonographic outcome in the short term, but
does not allow the long-term clinical evaluation of this
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the proportion of POL-foam entering the deep venous
system when the multiple small-dose injection technique
was used. Spasm of the GSV and varicose tributary veins
was confirmed using duplex ultrasound, and a significant
proportion of the sclerosant foam remained in the superfi-
cial venous system. One possible explanation for this could
be migration of excess POL-foam via perforating veins or
the SFJ into the deep venous system in patients treated
with a few injections, each with a large amount of foam.
Conclusion
The present findings indicate that multiple small-dose
injections can reduce the amount of sclerosant foam to
treat patients with superficial venous insufficiency and lead
to less foam entering the deep veins. This strategy could be
added to other methods aimed at minimising the systemic
side effects of foam sclerotherapy.
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